APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-PD-1 MAb

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Anti-PD-1 MAb Market Outlook and Growth Opportunities 2026

2 January 2026191 pages

Choose your research edition.

Industry ResearchAnti-PD-1 MAb Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-PD-1 MAb Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Anti-PD-1 MAb Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-PD-1 MAb Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-PD-1 MAb Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Anti-PD-1 MAb market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Anti-PD-1 MAb is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Anti-PD-1 MAb is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Anti-PD-1 MAb is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Anti-PD-1 MAb market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Anti-PD-1 MAb market include Thermo Fisher Scientific, Merck KGaA, Ximbio, Sino Biological, OriGene Technologies, Leinco Technologies, Elabscience and BioVision, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Anti-PD-1 MAb market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Anti-PD-1 MAb and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anti-PD-1 MAb revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Anti-PD-1 MAb market.

Anti-PD-1 MAb Segment by Company

Thermo Fisher Scientific

Merck KGaA

Ximbio

Sino Biological

OriGene Technologies

Leinco Technologies

Elabscience

BioVision

Anti-PD-1 MAb Segment by Type

1mg

2.5mg

Others

Anti-PD-1 MAb Segment by Application

Pharmaceutical

Research

Other

Anti-PD-1 MAb Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Anti-PD-1 MAb status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Anti-PD-1 MAb key companies, revenue, market share, and recent developments.

3. To split the Anti-PD-1 MAb breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Anti-PD-1 MAb market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Anti-PD-1 MAb significant trends, drivers, influence factors in global and regions.

6. To analyze Anti-PD-1 MAb competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-PD-1 MAb market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-PD-1 MAb and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-PD-1 MAb.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Anti-PD-1 MAb industry.

Chapter 3: Detailed analysis of Anti-PD-1 MAb company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Anti-PD-1 MAb in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Anti-PD-1 MAb in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Anti-PD-1 MAb Industry Trends Table 2. Anti-PD-1 MAb Industry Drivers Table 3. Anti-PD-1 MAb Industry Opportunities and Challenges Table 4. Anti-PD-1 MAb Industry Restraints Table 5. Global Anti-PD-1 MAb Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Anti-PD-1 MAb Revenue Share by Company (2021-2026) Table 7. Global Anti-PD-1 MAb Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Anti-PD-1 MAb Key Company Manufacturing Base & Headquarters Table 9. Global Anti-PD-1 MAb Company, Product Type & Application Table 10. Global Anti-PD-1 MAb Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Anti-PD-1 MAb by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of 1mg Table 15. Significant Companies of 2.5mg Table 16. Significant Companies of Others Table 17. Global Anti-PD-1 MAb Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Anti-PD-1 MAb Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Anti-PD-1 MAb Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Anti-PD-1 MAb Sales Value Share by Type (2021-2026) Table 21. Global Anti-PD-1 MAb Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Pharmaceutical Table 23. Significant Companies of Research Table 24. Significant Companies of Other Table 25. Global Anti-PD-1 MAb Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Anti-PD-1 MAb Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Anti-PD-1 MAb Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Anti-PD-1 MAb Sales Value Share by Application (2021-2026) Table 29. Global Anti-PD-1 MAb Sales Value Share by Application (2027-2032) Table 30. Global Anti-PD-1 MAb Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Anti-PD-1 MAb Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Anti-PD-1 MAb Sales Value Share by Region (2021-2026) Table 33. Global Anti-PD-1 MAb Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Anti-PD-1 MAb Sales Value Share by Region (2027-2032) Table 35. Global Anti-PD-1 MAb Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Anti-PD-1 MAb Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Anti-PD-1 MAb Sales Value Market Share by Country (2021-2026) Table 38. Global Anti-PD-1 MAb Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Anti-PD-1 MAb Sales Value Market Share by Country (2027-2032) Table 40. Thermo Fisher Scientific Company Information Table 41. Thermo Fisher Scientific Business Overview Table 42. Thermo Fisher Scientific Anti-PD-1 MAb Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Thermo Fisher Scientific Anti-PD-1 MAb Product Portfolio Table 44. Thermo Fisher Scientific Recent Development Table 45. Merck KGaA Company Information Table 46. Merck KGaA Business Overview Table 47. Merck KGaA Anti-PD-1 MAb Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Merck KGaA Anti-PD-1 MAb Product Portfolio Table 49. Merck KGaA Recent Development Table 50. Ximbio Company Information Table 51. Ximbio Business Overview Table 52. Ximbio Anti-PD-1 MAb Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Ximbio Anti-PD-1 MAb Product Portfolio Table 54. Ximbio Recent Development Table 55. Sino Biological Company Information Table 56. Sino Biological Business Overview Table 57. Sino Biological Anti-PD-1 MAb Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Sino Biological Anti-PD-1 MAb Product Portfolio Table 59. Sino Biological Recent Development Table 60. OriGene Technologies Company Information Table 61. OriGene Technologies Business Overview Table 62. OriGene Technologies Anti-PD-1 MAb Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. OriGene Technologies Anti-PD-1 MAb Product Portfolio Table 64. OriGene Technologies Recent Development Table 65. Leinco Technologies Company Information Table 66. Leinco Technologies Business Overview Table 67. Leinco Technologies Anti-PD-1 MAb Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Leinco Technologies Anti-PD-1 MAb Product Portfolio Table 69. Leinco Technologies Recent Development Table 70. Elabscience Company Information Table 71. Elabscience Business Overview Table 72. Elabscience Anti-PD-1 MAb Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Elabscience Anti-PD-1 MAb Product Portfolio Table 74. Elabscience Recent Development Table 75. BioVision Company Information Table 76. BioVision Business Overview Table 77. BioVision Anti-PD-1 MAb Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. BioVision Anti-PD-1 MAb Product Portfolio Table 79. BioVision Recent Development Table 80. Research Programs/Design for This Report Table 81. Authors List of This Report Table 82. Secondary Sources Table 83. Primary Sources List of Figures Figure 1. Anti-PD-1 MAb Product Image Figure 2. Global Anti-PD-1 MAb Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-PD-1 MAb Market Size (2021-2032) & (US$ Million) Figure 4. Global Anti-PD-1 MAb Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. 1mg Image Figure 8. 2.5mg Image Figure 9. Others Image Figure 10. Global Anti-PD-1 MAb Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Anti-PD-1 MAb Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Anti-PD-1 MAb Sales Value Share by Type (2021-2032) Figure 13. Pharmaceutical Image Figure 14. Research Image Figure 15. Other Image Figure 16. Global Anti-PD-1 MAb Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Anti-PD-1 MAb Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Anti-PD-1 MAb Sales Value Share by Application (2021-2032) Figure 19. Global Anti-PD-1 MAb Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Anti-PD-1 MAb Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Anti-PD-1 MAb Sales Value (2021-2032) & (US$ Million) Figure 22. North America Anti-PD-1 MAb Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Anti-PD-1 MAb Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Anti-PD-1 MAb Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Anti-PD-1 MAb Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Anti-PD-1 MAb Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Anti-PD-1 MAb Sales Value (2021-2032) & (US$ Million) Figure 28. South America Anti-PD-1 MAb Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Anti-PD-1 MAb Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Anti-PD-1 MAb Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Anti-PD-1 MAb Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Anti-PD-1 MAb Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Anti-PD-1 MAb Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Anti-PD-1 MAb Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Anti-PD-1 MAb Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Anti-PD-1 MAb Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Anti-PD-1 MAb Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Anti-PD-1 MAb Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Anti-PD-1 MAb Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Anti-PD-1 MAb Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Anti-PD-1 MAb Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Anti-PD-1 MAb Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Anti-PD-1 MAb Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Anti-PD-1 MAb Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Anti-PD-1 MAb Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Anti-PD-1 MAb Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Anti-PD-1 MAb Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Anti-PD-1 MAb Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Anti-PD-1 MAb Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Anti-PD-1 MAb Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Anti-PD-1 MAb Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Anti-PD-1 MAb Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Anti-PD-1 MAb Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Anti-PD-1 MAb Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Anti-PD-1 MAb Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Anti-PD-1 MAb Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Anti-PD-1 MAb Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Anti-PD-1 MAb Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • 1mg
  • 2.5mg
  • Others
Applications
  • Pharmaceutical
  • Research
  • Other
Companies covered
  • Thermo Fisher Scientific
  • Merck KGaA
  • Ximbio
  • Sino Biological
  • OriGene Technologies
  • Leinco Technologies
  • Elabscience
  • BioVision

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Anti-PD-1 MAb Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Anti-PD-1 MAb Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Anti-PD-1 MAb Market Dynamics
  1. 2.1 Anti-PD-1 MAb Industry Trends
  2. 2.2 Anti-PD-1 MAb Industry Drivers
  3. 2.3 Anti-PD-1 MAb Industry Opportunities and Challenges
  4. 2.4 Anti-PD-1 MAb Industry Restraints
3 Anti-PD-1 MAb Market by Company
  1. 3.1 Global Anti-PD-1 MAb Company Revenue Ranking in 2025
  2. 3.2 Global Anti-PD-1 MAb Revenue by Company (2021-2026)
  3. 3.3 Global Anti-PD-1 MAb Company Ranking (2024-2026)
  4. 3.4 Global Anti-PD-1 MAb Company Manufacturing Base and Headquarters
  5. 3.5 Global Anti-PD-1 MAb Company Product Type and Application
  6. 3.6 Global Anti-PD-1 MAb Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Anti-PD-1 MAb Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Anti-PD-1 MAb Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Anti-PD-1 MAb Market by Type
  1. 4.1 Anti-PD-1 MAb Type Introduction
  2. 4.1.1 1mg
  3. 4.1.2 2.5mg
  4. 4.1.3 Others
  5. 4.2 Global Anti-PD-1 MAb Sales Value by Type
  6. 4.2.1 Global Anti-PD-1 MAb Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Anti-PD-1 MAb Sales Value by Type (2021-2032)
  8. 4.2.3 Global Anti-PD-1 MAb Sales Value Share by Type (2021-2032)
5 Anti-PD-1 MAb Market by Application
  1. 5.1 Anti-PD-1 MAb Application Introduction
  2. 5.1.1 Pharmaceutical
  3. 5.1.2 Research
  4. 5.1.3 Other
  5. 5.2 Global Anti-PD-1 MAb Sales Value by Application
  6. 5.2.1 Global Anti-PD-1 MAb Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Anti-PD-1 MAb Sales Value by Application (2021-2032)
  8. 5.2.3 Global Anti-PD-1 MAb Sales Value Share by Application (2021-2032)
6 Anti-PD-1 MAb Regional Value Analysis
  1. 6.1 Global Anti-PD-1 MAb Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anti-PD-1 MAb Sales Value by Region (2021-2032)
  3. 6.2.1 Global Anti-PD-1 MAb Sales Value by Region: 2021-2026
  4. 6.2.2 Global Anti-PD-1 MAb Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Anti-PD-1 MAb Sales Value (2021-2032)
  7. 6.3.2 North America Anti-PD-1 MAb Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Anti-PD-1 MAb Sales Value (2021-2032)
  10. 6.4.2 Europe Anti-PD-1 MAb Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Anti-PD-1 MAb Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Anti-PD-1 MAb Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Anti-PD-1 MAb Sales Value (2021-2032)
  16. 6.6.2 South America Anti-PD-1 MAb Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Anti-PD-1 MAb Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Anti-PD-1 MAb Sales Value Share by Country, 2025 VS 2032
7 Anti-PD-1 MAb Country-level Value Analysis
  1. 7.1 Global Anti-PD-1 MAb Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Anti-PD-1 MAb Sales Value by Country (2021-2032)
  3. 7.2.1 Global Anti-PD-1 MAb Sales Value by Country (2021-2026)
  4. 7.2.2 Global Anti-PD-1 MAb Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Anti-PD-1 MAb Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Anti-PD-1 MAb Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Anti-PD-1 MAb Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Anti-PD-1 MAb Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Anti-PD-1 MAb Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Anti-PD-1 MAb Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Anti-PD-1 MAb Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Anti-PD-1 MAb Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Anti-PD-1 MAb Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Anti-PD-1 MAb Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Anti-PD-1 MAb Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Anti-PD-1 MAb Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Anti-PD-1 MAb Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Anti-PD-1 MAb Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Anti-PD-1 MAb Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Anti-PD-1 MAb Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Anti-PD-1 MAb Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Anti-PD-1 MAb Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Anti-PD-1 MAb Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Anti-PD-1 MAb Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Anti-PD-1 MAb Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Anti-PD-1 MAb Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Anti-PD-1 MAb Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Anti-PD-1 MAb Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Anti-PD-1 MAb Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Anti-PD-1 MAb Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Anti-PD-1 MAb Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Anti-PD-1 MAb Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Anti-PD-1 MAb Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Anti-PD-1 MAb Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Thermo Fisher Scientific
  2. 8.1.1 Thermo Fisher Scientific Company Information
  3. 8.1.2 Thermo Fisher Scientific Business Overview
  4. 8.1.3 Thermo Fisher Scientific Anti-PD-1 MAb Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Thermo Fisher Scientific Anti-PD-1 MAb Product Portfolio
  6. 8.1.5 Thermo Fisher Scientific Recent Developments
  7. 8.2 Merck KGaA
  8. 8.2.1 Merck KGaA Company Information
  9. 8.2.2 Merck KGaA Business Overview
  10. 8.2.3 Merck KGaA Anti-PD-1 MAb Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck KGaA Anti-PD-1 MAb Product Portfolio
  12. 8.2.5 Merck KGaA Recent Developments
  13. 8.3 Ximbio
  14. 8.3.1 Ximbio Company Information
  15. 8.3.2 Ximbio Business Overview
  16. 8.3.3 Ximbio Anti-PD-1 MAb Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Ximbio Anti-PD-1 MAb Product Portfolio
  18. 8.3.5 Ximbio Recent Developments
  19. 8.4 Sino Biological
  20. 8.4.1 Sino Biological Company Information
  21. 8.4.2 Sino Biological Business Overview
  22. 8.4.3 Sino Biological Anti-PD-1 MAb Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sino Biological Anti-PD-1 MAb Product Portfolio
  24. 8.4.5 Sino Biological Recent Developments
  25. 8.5 OriGene Technologies
  26. 8.5.1 OriGene Technologies Company Information
  27. 8.5.2 OriGene Technologies Business Overview
  28. 8.5.3 OriGene Technologies Anti-PD-1 MAb Revenue and Gross Margin (2021-2026)
  29. 8.5.4 OriGene Technologies Anti-PD-1 MAb Product Portfolio
  30. 8.5.5 OriGene Technologies Recent Developments
  31. 8.6 Leinco Technologies
  32. 8.6.1 Leinco Technologies Company Information
  33. 8.6.2 Leinco Technologies Business Overview
  34. 8.6.3 Leinco Technologies Anti-PD-1 MAb Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Leinco Technologies Anti-PD-1 MAb Product Portfolio
  36. 8.6.5 Leinco Technologies Recent Developments
  37. 8.7 Elabscience
  38. 8.7.1 Elabscience Company Information
  39. 8.7.2 Elabscience Business Overview
  40. 8.7.3 Elabscience Anti-PD-1 MAb Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Elabscience Anti-PD-1 MAb Product Portfolio
  42. 8.7.5 Elabscience Recent Developments
  43. 8.8 BioVision
  44. 8.8.1 BioVision Company Information
  45. 8.8.2 BioVision Business Overview
  46. 8.8.3 BioVision Anti-PD-1 MAb Revenue and Gross Margin (2021-2026)
  47. 8.8.4 BioVision Anti-PD-1 MAb Product Portfolio
  48. 8.8.5 BioVision Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst